Companies › Aurigene Discovery Technologies
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AUR107 AURKA inhibitor | – | Phase 1 | Relapsed Malignant Solid Neoplasm | Jan 2027 |
| AUR112 | – | Phase 1 | Relapsed Advanced Lymphomas | Jan 2027 |
| AUR108 HDM2 inhibitor | – | Phase 1 | Relapsed Advanced Lymphomas | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05865002 | AUR107 | Phase 1 | Relapsed Malignant Solid Neoplasm | Oncology | Jan 2027 |
| NCT06755450 | AUR112 | Phase 1 | Relapsed Advanced Lymphomas | Oncology | Jan 2027 |
| NCT05984147 | AUR108 | Phase 1 | Relapsed Advanced Lymphomas | Oncology | Aug 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.